This report presents detailed analytical testing of Finasteride 0.25%, a topical formulation of this well-known 5-alpha-reductase inhibitor specifically designed for hair loss applications with reduced systemic exposure compared to oral administration. The assessment was conducted to verify the product's quality attributes, including purity, concentration accuracy, and stability characteristics through comprehensive analytical methodologies for enzyme inhibitor compounds that require precise quality assurance to ensure reliable efficacy while minimizing potential systemic effects through controlled topical delivery.
HPLC, Espectrofotometría UV-Vis
| Parameter | Value |
|---|---|
| Sample Identification | FINASTERIDE 0.25% (Lote# K0J1H2G3F4-2024) |
| Concentration | 0.5 mg/mL ± 0.03 |
| Purity | 98.3% |
| Impurities | < 1.7% |
The analytical results show that Finasteride exhibits excellent purity at 98.3%, which is particularly important for a potent enzyme inhibitor compound where precise concentration directly affects therapeutic efficacy and safety margins. The concentration of 0.5 mg/mL indicates precise manufacturing control and excellent product consistency for this low-concentration formulation. Impurity levels were minimal at less than 1.7%, consisting mainly of trace degradation products that are well-characterized. UV-Vis spectroscopy confirmed the characteristic absorption pattern and provided additional quality assurance data specific to the compound's stability in the topical vehicle.
Finasteride 0.25% exceeds quality specifications with high purity levels and precise concentration control. The minimal impurity profile confirms excellent manufacturing practices, making this topical formulation highly suitable for therapeutic use in hair loss management with reliable 5-alpha-reductase inhibition and reduced systemic exposure compared to oral administration, offering patients important benefits in safety profile while maintaining therapeutic efficacy for androgenetic alopecia treatment.
